Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiodesixBDSX -3.84%53 5-Year Yield-on-Cost % is 0.00 as of Aug. 18, 2026. GuruFocus rates BDSX with a GF Score™ of 53/100 and a GF Value™ of $21.33 (Fairly Valued). The stock has 5 warning signs investors should review. Among 62 Medical Diagnostics & Research companies, Biodesix ranks worse than 1612901.61% on this metric.
Biodesix's yield on cost for the quarter that ended in Jun. 2026 was 0.00.
The historical rank and industry rank for Biodesix's 5-Year Yield-on-Cost % or its related term are showing as below:
BDSX's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.395 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Biodesix 5-Year Yield-on-Cost % Related Terms
BDSX vs IMDX, XGN, BNR: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Biodesix's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biodesix 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Biodesix's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Biodesix is calculated as
Biodesix (BDSX) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 18, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Biodesix and its competitors. According to the industry distribution chart, Biodesix ranks #999999 out of 62 companies in the Medical Diagnostics & Research industry.
Is Biodesix's 5-Year Yield-on-Cost % too high?
Biodesix's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Biodesix ranks #999999 out of 62 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Biodesix has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biodesix's 5-Year Yield-on-Cost % compare to IMDX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Biodesix ranks #999999 out of 62 companies for 5-Year Yield-on-Cost %. This places Biodesix in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.40, based on 62 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Biodesix and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biodesix's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodesix stock overvalued right now?
Based on GuruFocus' analysis, Biodesix (BDSX) is currently considered Fairly Valued. The stock's GF Value™ is $21.33, compared to a current price of $22.55 — trading 5.7% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Biodesix's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Biodesix (BDSX), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biodesix (BDSX) Overvalued in 2026?
Based on GuruFocus' analysis, Biodesix stock appears to be overvalued.
The current stock price of $22.55 is trading 5.7% above its estimated GF Value™ of $21.33.
GuruFocus considers Biodesix to be Fairly Valued.
Key valuation signals for BDSX:
5-Year Yield-on-Cost %: 0.00
GF Value™: $21.33 vs. price of $22.55 (5.7% above fair value)
No single metric tells the full story. See the BDSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
53GF Score
Get the complete analysis for BDSX
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDSX has been successfully added to your 
